Agenus (AGEN) to Release Quarterly Earnings on Tuesday

Agenus (NASDAQ:AGEN) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Agenus to post earnings of ($1.27) per share and revenue of $28.0960 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 9:30 AM ET.

Agenus Stock Up 1.4%

AGEN stock opened at $2.96 on Friday. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34. The company has a market cap of $100.67 million, a P/E ratio of -1.39 and a beta of 1.57. The business has a fifty day moving average of $3.25 and a 200-day moving average of $3.83.

Institutional Investors Weigh In On Agenus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Arrowstreet Capital Limited Partnership acquired a new position in shares of Agenus during the 3rd quarter worth about $120,000. Virtu Financial LLC acquired a new stake in shares of Agenus in the 4th quarter valued at approximately $108,000. Engineers Gate Manager LP bought a new position in Agenus during the 2nd quarter worth approximately $108,000. Tower Research Capital LLC TRC boosted its stake in Agenus by 265.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 15,893 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in Agenus during the first quarter valued at approximately $88,000. Institutional investors own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.